M
Molecular Partners AG (MOLN)
NMS – Real vaqt narxi. Valyuta: USD
4.04
-0.09 (-2.18%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
4.04
-0.09 (-2.18%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Molecular Partners AG, klinik tadqiqot bosqichidagi biotexnologiya kompaniyasi, Shveytsariyada onkologiya kasalliklarini davolash uchun mo'ljallangan ankyrin takroriy oqsillari terapiyasini loyihalashtiradi va ishlab chiqadi. Uning mahsulot quvuri MP0317ni o'z ichiga oladi, bu ilg'or qattiq o'smalarni davolash uchun 2-bosqich klinik sinovda; MP053, yangi tetra-spetsifik T hujayrali DARPin, bu o'tkir miyeloid leykemiyani davolash uchun 1-bosqich klinik sinovda; va MP0712, 212Pb Radio-DARPin terapiyasi (RDT) nomzodi, o'simtaga bog'liq oqsil delta-like ligand 3 (DLL3) ga qaratilgan, bu SCLC va neyroendokrin o'smalarni davolash uchun 1-bosqich klinik sinovda. Shuningdek, u CD3 x kostim xni davolash uchun Switch-DARPin T hujayrali engejerini tadqiq qiladi; va MP0726, tuxumdon saratoni va boshqa MSLN ifodalovchi saratonlarni davolash uchun Radio-DARPin terapiyasi. Bundan tashqari, kompaniya hematopoetik ildiz hujaychalar transplantatsiyasini tayyorlash uchun CD16a, c-KIT va CD47 ga qaratilgan Switch-DARPin nomzodi MP0621ni ishlab chiqadi; va Radio-DARPin terapiyasi (RDT) platformasi, radioaktiv yuklarni qattiq o'smalarga samarali va selektiv etkazib berish tizimi. U Orano Med SAS bilan yangi Radio-DARPin terapiyalarini ishlab chiqish bo'yicha hamkorlik shartnomasiga ega va qo'shimcha oltita maqsadli alfa terapiyasi nomzodlari va Eckert & Ziegler SE bilan Radio-DARPin terapiyalarini ishlab chiqish bo'yicha hamkorlik shartnomasiga ega. Molecular Partners AG 2004 yilda tashkil etilgan va Shveytsariyaning Shlieren shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Michael Tobias Stumpp Ph.D. | Co-Founder, Executive VP of Projects & Member of Management Board |
| Dr. Pamela A. Trail Ph.D. | Strategic Consultant |
| Dr. Patrick Amstutz Ph.D. | Co-Founder, CEO, Member of Management Board & Director |
| Dr. Philippe Legenne M.B.A., M.D. | Chief Medical Officer & Member of the Management Board |
| Mr. Alexander Zurcher | COO & Member of Management Board |
| Mr. Daniel Steiner Ph.D. |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-01 | 6-K | f6k_050126.htm |
| 2026-04-14 | 6-K | f6k_041426.htm |
| 2026-03-30 | 6-K | molecularpartners-form6xkm.htm |
| 2026-03-13 | 6-K | f6k_031326.htm |
| 2026-03-12 | 6-K | molecularpartners-form6xk2.htm |
| 2026-02-02 | 6-K | f6k_020226.htm |
| 2026-01-12 | 6-K | f6k_011226.htm |
| 2025-12-08 | 6-K | f6k_120825.htm |
| 2025-11-12 | 6-K | f6k_111225.htm |
| 2025-10-30 | 6-K | q32025financialstatements.htm |
| Senior Vice President of Research & Technology |
| Mr. Martin Steegmaier Ph.D. | Chief Scientific Officer & Member of the Management Board |
| Mr. Michael Pitzner | Executive VP of Partnering & General Counsel |
| Mr. Robert Hendriks | Senior VP of Finance & Member of Management Board |
| Ms. Renate Gloggner | Executive VP of People & Community and Member of Management Board |